INS and breast cancer: Taken together, these results indicate that insulin activates the PI3K/AKT signalling axis in both triple-negative and luminal breast cancer subtypes, whereas ERK1/2 pathway activation is restricted to the hormone receptor positive MCF-7, reflecting a subtype specific divergence in downstream insulin signalling.